Jan, 11 2018 11:46 JST

Source: Eisai

Eisai Completes Construction of Oral Solid Dose Production Facility at New Suzhou Plant in China

TOKYO, Jan, 11 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has completed construction of a new oral solid dose (OSD) production facility and an administration building at the site of its new Suzhou plant located within the Suzhou Industrial Park.

Aiming to further expand its contribution to patients in China, Eisai has been working to establish a new Suzhou plant on a new industrial site more than five times larger than the current Suzhou Plant (OSD production facility) to further strengthen the stable supply chain as well as improve production efficiency.

ECI established a parenteral facility in November 2014, where it manufactures the injection formulation of Methycobal. The newly completed OSD production facility stands three floors aboveground and contains floor space of approximately 20,240 m2, and its production capacity (formulation of approximately 3 billion tablets / packaging for approximately 5 billion tablets per year) is approximately double that of the current Suzhou Plant. Operations are expected to commence in the second half of fiscal 2018, and the new OSD facility will handle the formulation and packaging of oral solid dose products such as Methycobal, Aricept and Pariet for the domestic Chinese market. The current plant will be closed after operations fully commence at the new Suzhou Plant's OSD production facility.

Eisai's business operations in China are one of its core businesses which is third-largest in scale after Japan and the United States. Through the completion of the OSD production facility at the new Suzhou Plant, Eisai seeks to strengthen its in-house domestic production system in China and expand its stable supply chain of high quality pharmaceuticals, contributing to increasing the benefits to patients and their families in China.

About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Eisai Co., Ltd.
Public Relations Department
Source: Eisai
Sectors: BioTech

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
March 14 2018 11:16 JST
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
March 08 2018 13:33 JST
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
March 08 2018 12:00 JST
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan
February 27 2018 09:33 JST
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)
February 21 2018 08:25 JST
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
February 16 2018 07:34 JST
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
February 12 2018 09:03 JST
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan
February 01 2018 16:20 JST
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib)
January 22 2018 09:51 JST
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan
January 20 2018 18:32 JST
More Press release >>

Latest Press Release

More Latest Release >>